Millers of Wyckoff, Inc., Wyckoff, NJ
Is Millers of Wyckoff, Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Millers of Wyckoff, Inc. hold a New Jersey pharmacy license?
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The Texas State Board of Pharmacy also lists nonresident license 35591 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status Active, as of Nov 15, 2026. The California State Board of Pharmacy also lists nonresident license NRP 2219 for Millers Of Wyckoff Inc, Wyckoff, NJ, status Active, as of Nov 6, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 6085 for Millers of Wyckoff Inc, Wyckoff, NJ, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054023595 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status ACTIVE, license 054018003 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP, license 054021124 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP and license 054023471 for MILLERS OF WYCKOFF INC, WYCKOFF, NJ, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0000894 for MILLERS OF WYCKOFF, WYCKOFF, NJ, status ACTIVE (CURRENT), as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0013192 for Millers of Wyckoff, WYCKOFF, NJ, status Active, license A9-0001121 for Millers of Wyckoff, Wyckoff, NJ, status Closed and license A9-0002292 for Millers of Wyckoff, WYCKOFF, NJ, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301009862 for Millers of Wyckoff, Inc., Wyckoff, NJ, status Active, as of Nov 10, 2026.
Has Millers of Wyckoff, Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Feb 26, 2019), 1 untitled letter (Dec 1, 2021), 1 state referral letter (Feb 26, 2019) and 2 FMD-145 letters (Feb 26, 2019 and Jun 17, 2022) for Millers of Wyckoff, Inc. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Millers of Wyckoff, Inc.
- Location
- Wyckoff, NJ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jun 17, 2022
- FDA Data Dashboard inspections
- 3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
- Form 483 text on this page
- 2 Form 483s, 14 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Millers of Wyckoff, Inc., a 503A facility, with 6 dated actions.
| Document | |||
|---|---|---|---|
| Jun 17, 2022 | FMD-145 letter | FMD-145 Letter Issued 06/17/2022 | Not linked by FDA |
| Dec 1, 2021 | Untitled letter | Untitled Letter Issued 12/01/2021 | FDA copy (archived) |
| Oct 9, 2020 | Form 483 | 483 Issued 10/09/2020 | FDA copy (archived) |
| Feb 26, 2019 | Warning letter close-out | Warning Letter CloseOut (02/26/2019) | FDA copy (archived) |
| Feb 26, 2019 | FMD-145 letter | FMD-145 Letter Issued 02/26/2019 | FDA copy (archived) |
| Feb 26, 2019 | State referral letter | State Referral Letter Issued 02/26/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Millers of Wyckoff, Inc., Wyckoff, NJ (FEI number 3004600183), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 9, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3004600183 | 1132682 |
| May 18, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3004600183 | 1018468 |
| Jul 16, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3004600183 | 934124 |
Form 483s FDA has published for this site
- Oct 9, 2020: Form 483 to Millers of Wyckoff, Inc., published Dec 22, 2020. fda.gov
- Jul 24, 2017: Form 483 to Millers of Wyckoff, Inc., published Jan 17, 2024. fda.gov
- Sep 16, 2015: Form 483 to Millers of Wyckoff, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 14 numbered observations in all, across 2 inspections ending Jul 16, 2015 to Oct 9, 2020. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Sep 16, 2020 to Oct 9, 2020: 2 observations
- Firm on the cover
- Millers of Wyckoff, Inc, 678 Wyckoff Avenue, Wyckoff, NJ, 07481
- FEI number
- 3004600183
- Establishment type on the cover
- Producer of Sterile and Non-Sterile Drugs
- FDA district office on the cover
- Division of Pharmaceutical Quality Operations 110 Waterview Blvd, 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Hazardous drugs were produced without providing adequate cleaning of utensils to prevent cross contamination.
Specifically, your firm produces potent drugs including, but not limited to Progesterone, Testosterone, or a combination of these drug products from <Redacted B4> Active Pharmaceutical Ingredients (APis). Utensils used in the production of these potent drugs, such as, spatulas, jars and glass beakers are not dedicated and not cleaned with a process that utilizes an agent to deactivate residual APis.
Your firm utilizes a store-bought brand liquid dish detergent and potable water for cleaning of theses utensils in the processing of potent APis. The following potent drug products were observed being prepared and produced using the non-sterile hazard production room on 09/l7/2020:
A) Testosterone Topical 50mg/gm 15% Cream Rx: <Redacted B6> Lot# 09172020@22, BUD: 10/22/2020, Date Made: 09/17/2020
l
B.) BIEST <Redacted B4> Progesterone 2mg/100mg, Rx: <Redacted B6> Lot# 09172020@15, BUD: 12/16/2020, Date Made: 09/17/2020
15 4 C.) BIEST <Redacted B4> Progesterone 2.5mg/125mg, RX: <Redacted B6> Lot# 09172020@25, BUD: 12/16/2020, Date Made: 09/17/2020
Observation 2
Inadequate pressure differentials between higher quality air rooms and lower quality air rooms were observed.
Specifically, your records of differential room pressures are inadequate, in that, you do not record the quantitative value of the pressures. Additionally, your record of differential room pressures failed to record pressure excursions for your Sterile Hazardous Room in the following instances:
Your most recent cleanroom certification report, dated: 08/14/2020, documents that the Sterile Hazardous Room (ISO 7) pressure was recorded at (negative)-0.064" w.c. According to your specification, the acceptance range for differential pressure of this room is between <Redacted B4> In this instance, the reported differential pressure reading was out of specification. However, you continued to use this room as well as, adjacent cleanrooms for production of sterile drug products.
In addition, on 09/25/2020, I observed that the Magnahelic equipment used to monitor the pressure differential reading for the Hazardous Room was (negative) -0.11" w.c, which was not within specifications.
Inspection Jun 29, 2015 to Jul 16, 2015: 12 observations
- Firm on the cover
- Millers of Wyckoff, Inc., 678 Wyckoff Ave, Wyckoff, NJ 07481 - 1430
- FEI number
- 3004600183
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written, and followed.
Specifically, the following poor aseptic techniques were observed during processing on 6/29/20 I5 and 6/30/2015 :
Materials such as syringes, wrapped sterile and vials were not wiped down with Ster i le REDACTED (b)(4) prior to introduction into the REDACTED (b)(4) Incomplete sanitization of the stopper of each vial of drug product REDACTED (b)(4) Processing of product was performed on top of the sterile gloves wrapper, rather than worksurface. Gloves worn during processing in the REDACTED (b)(4) are not changed or sanitized with sterile REDACTED (b)(4) between production of different products and/or lots. · Disposable, non-sterile laboratory coats used during processing of drug products were reused, even after falling on the floor.
Observation 2
Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.
Specifically, there is a lack of potency and sterility assurance for preserved and non-preserved sterile preparations in that beyond use dates, up to 3 months, are assigned without stability data and the container closure integrity of the bottles has not been established. Examples of products include : Buprenorphine (multidose vial) 0.3mg/mL, Lot # 02172015@24; Procain e (Buffered) (PF) 1% injectable, Lot# 04212015@17; Magnesium Sulfate Lot # 05202015@11; and Methylcobalamin(P ) 25mg/mL, Lot# 04302015@20; Cefazolin Ophthalmic (PF) 50mg/mL Solution, Lot# 04212015@26; and Methylprednison e (PF) eye drops, Lot# 05152015@1.
ster
Additionally, there is a l ack of test data to support that REDACTED (b)(4) , which have been REDACTED (b)(4) sterilized when produced, can be REDACTED (b)(4) to ensure sterility remains.
.t
Observation 3
Each batch of drug product purporting to be sterile is not laboratory tested to determine conformance to such requirements.
Specifically,
A . There is no documented test method for sterility testing for all products, except for Trimix (various formulations). The executed method has not been defined to be a compendial method or a method, which has been shown to be as good or better than the compendial method. In addition, on 6/29/2015, Pharmacist REDACTED (b)(4) failed to assure us that the executed sterility testing being performed was as per method suitability conducted by a contract testing laboratoty. Furthermore, negative controls are not run for each sterility test performed.
B. Endotoxin testing is not performed on all finished lots of drug products. For example REDACTED (b)(4) x10mL vials, with 5 mL in each vial, of Trimix lA Lot #04212015@10 were produced on 4/21/2015; however testing does not include en dotoxin results.
Observation 4
Equipment and utensils are not maintained at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, balance REDACTED (b)(4) Model# REDACTED (b)(4), which is used to weigh non-sterile ingredie nts has not been calibrate d to ensure that the scale can we igh across its minimum range REDACTED (b) (4) The mini mum we ight used to calibrate the balance was REDACTED (b)(4) in 2014 and REDACTED ( b)(4) in 20 15 . Examples ofingredients which have been weighed that are les s than REDACTED (b)(4) include: REDACTED (b)(4)g procaine to compound procaine (buffered) (PF) 1% Lot# 04212015@17 and REDACTED (b)(4) of sodium molybdate REDACTED (b)(4) for Molybdenum(P) 25mcg/ML LOt # 06022015@5. Specifically, balance REDACTED (b)(4) Model# REDACTED (b)(4), which is used to weigh non-sterile ingredients has not been calibrated to ensure that the scale can weigh across its minimum range REDACTED (b)(4) The minimum weight used to calibrate the balance was REDACTED (b)(4) in 2014 and REDACTED (b)(4) in 2015. ...
Observation 5
Employees are not given training in the particular operations they perform as part of their function.
Specifically,
A. There is no documented microbiological training for the following tests and individuals who perform them:
1. Sterility and environmental testing by Pharmacist, REDACTED (b)(4). 2. Reading of microbiological assay results by Pharmacy Technician REDACTED (b)(4). 3. Performance of REDACTED (b)(4) by Pharmacist Intern, REDACTED (b)(4).
B. There is no documented training for Pharmacist REDACTED (b)(4) who performed physical testing for sterile compou nded finished products.
Observation 6
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions . .
Specifically,
A. Procedure SOP 3.03 Environmental Monitoring (EM) ofthe Sterile Compounding Area (Date Effective: 01-01-07) provides instructions on surface sampling technique and incubation; however, this procedure is not being followed. For example: use of environmental monitoring sampling supplies are not the same as described in the procedure, REDACTED (b)(4) was observed to be sampling multiple loca tions in th e REDACTED (b)(4 ) and all EM samples are not being incubated for the REDACTED (b)(4) temperature requirement.
Procedure SOP 3.03 Environmental Monitoring (EM) ofthe Sterile Compounding Area (Date Effective: 01-01-07) provides in structions on surface sampling technique and incubation; however, this procedure is not being followed. For example: use of environmental monitoring sampling supplies are not the same as described in the procedure, REDACTED (b)(4) was observed to be sampling multiple locations in the REDACTED (b)(4) and all EM samples are not being incubated for the REDACTED (b)(4) temperature requirement.
B. ...
Observation 7
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, for at least two products which the firm has tested, including Alprostadil 10mcg/mL Lot# 012420I2@I and Meth ylcobalamin(P) 25mcg/mL Lot# 12042013@59, the testing for these lots resulted in a potency outside of 139% and 72%, respectively. Methylcobalamin(P) 25mcg/mL Lot# 12042013@59 was not dispensed; however the firm has produced this formulation since and has dispensed it as Lot# 06042015@37 without ensuring that the potency is within specifications.
• Alprostadil l0mcg/mL Lot # 01242012@1, tested on 1/26/2012, resulted in a potency of 139%. The product was di spensed to a patient on 1/23/2012. • Methylcobalamin(P) 25mcg/mL Lot# 12042013@59, tested on 1/16/2014, resulted in a potency of 72.2%. The lot was not dispensed; however the firm has produced this formulation since without investigating the failure. Most recently , Methylcobalamin(P) 25mcg/ml has been dispensed as Lot# 06042015@37 ...
Observation 8
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic conditions.
Specifically, the firm has not demonstrated the efficacy of their disinfectants, REDACTED ( b)(4), Steri le REDACTED (b)(4) and Sterile REDACTED (b)(4) %, which are used to clean the firm's REDACTED (b)(4) and ISO 8 anteroom.
Additionally, we did not observe personnel adhhering to the established contact times for their disinfectant agents as noted in
SOP 3. 02 Cleaning and Ma intenance o f the Clean Room facility (Date Effective: 01-01-07).
Observation 9
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactor y conformance to the final specifications prior to release.
Specifically,
A. Visual inspection ofAlprostadil 20mcg/mL Lot# 06252015@31 on 6/29/2015 was not documented within the batch
record as per procedure SOP 6.02 Sterile Compounding Finished Preparation Testing (Date Effective: 01-01-07). This p roduct was delivered to the customer on 6/30/2015.
B. During compounding of TriMix STD Mayo Lot# 06302015@14, we observed that the operator did not conduct a visual check of REDACTED (b)(4) to REDACTED (b)(4) ofPhentolami ne. There are no procedures to ensure that this quality control step is taken REDACTED (b)(4). We observed non-dissolved in the REDACTED (b)(4)
Observation 10
Procedures designed to prevent microbiologicaJ contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Specifically, media fill simulations are not representive of the preparation ofa
septically fil led sterile products. For example, the sterile preparation of REDACTED (b)(4) Trimix 1A RX (PAPAV/PHENTOL/PGE1) 30MG/IMG/IOMCG/mL has REDACTED (b)(4) however, the media fill simulation is REDACTED (b)(4)
Observation 11
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, you have not qualified or audited your contract testing laboratories, used for potency, endotoxin, and sterility testin of Trimix finished products; however rely on their results.
Observation 12
The flow ofcomponents, drug product containers, in-process materials, and drug products though the building is not designed to prevent contamination.
Specifically, the ISO 8 anteroom contains a sink sourced with tap water that is located REDACTED (b)(4) w hich is used as the REDACTED (b)(4) the firm's REDACTED (b)(4)
Linked 483s whose text is not shown
- Jul 24, 2017: FDA document 106479: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).
| License | Type as the board gives it | Name on the board record | Location | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 35591 | Non Resident Sterile Compounding | MILLERS OF WYCKOFF INC | WYCKOFF, NJ | Active | No |
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NRP 2219 | Non Resident Pharmacy | Millers Of Wyckoff Inc | Wyckoff, NJ | Active |
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 6085 | OSP | Millers of Wyckoff Inc | Wyckoff, NJ | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054023595 | LICENSED PHARMACY | MILLERS OF WYCKOFF INC | WYCKOFF, NJ | ACTIVE |
| 054018003 | LICENSED PHARMACY | MILLERS OF WYCKOFF INC | WYCKOFF, NJ | CHANGE OF OWNERSHIP |
| 054021124 | LICENSED PHARMACY | MILLERS OF WYCKOFF INC | WYCKOFF, NJ | CHANGE OF OWNERSHIP |
| 054023471 | LICENSED PHARMACY | MILLERS OF WYCKOFF INC | WYCKOFF, NJ | CHANGE OF OWNERSHIP |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0000894 | NONRESIDENT PHARMACY | MILLERS OF WYCKOFF | WYCKOFF, NJ | ACTIVE (CURRENT) |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| A9-0013192 | Non Resident Pharmacy | Millers of Wyckoff | WYCKOFF, NJ | Active |
| A9-0001121 | Non Resident Pharmacy | Millers of Wyckoff | Wyckoff, NJ | Closed |
| A9-0002292 | Non Resident Pharmacy | Millers of Wyckoff | WYCKOFF, NJ | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301009862 | Pharmacy | Millers of Wyckoff, Inc. | Wyckoff, NJ | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Texas State Board of Pharmacy license file
- California State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- Texas State Board of Pharmacy disciplinary records
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.